Advanced search
Publication Cover
Journal of Investigative Surgery Volume 33, 2020 - Issue 6
Submit an article Journal homepage
918
Views
1
CrossRef citations to date
0
Altmetric
Commentary

CD24 as a Novel Predictive Biomarker in Patients with Hepatocellular Carcinoma: Friend or Foe?

Nikolaos Machairas3rd Department of Surgery, National and Kapodistrian University of Athens, Medical School, Athens, Greece; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-3239-3905
, MD, PhDORCID Icon,
Diamantis I. Tsilimigras3rd Department of Surgery, National and Kapodistrian University of Athens, Medical School, Athens, Greece; ORCID Iconhttp://orcid.org/0000-0002-3676-9263
, MDORCID Icon &
Demetrios MorisDepartment of Surgery, Duke University Medical Center, Durham, North Carolina, USAORCID Iconhttp://orcid.org/0000-0002-5276-0699
, MD, PhDORCID Icon
Pages 542-543 | Published online: 21 Dec 2018

References

  • Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301–1314. doi:10.1016/S0140-6736(18)30010-2.
  • IARC. Globocan 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. 2013. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx (Accessed July 2018).
  • Ghouri YA, Mian I, Rowe JH. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J Carcinog. 2017;16(1):1. doi:10.4103/jcar.JCar_9_16.
  • Beal EW, Tumin D, Kabir A, et al. Cohort contributions to race- and gender-specific trends in the incidence of hepatocellular carcinoma in the USA. World J Surg. 2018;42(3):835–840. doi:10.1007/s00268-017-4194-1.
  • Argyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the “Plague” of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. J BUON. 2017;22(1):6–20.
  • Beal EW, Tumin D, Kabir A, et al. Trends in the mortality of hepatocellular carcinoma in the United States. J Gastrointest Surg. 2017;21(12):2033–2038. doi:10.1007/s11605-017-3526-7.
  • El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340(10):745–750. doi:10.1056/NEJM199903113401001.
  • Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50(1):89–99. doi:10.1016/j.jhep.2008.07.029.
  • Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125(1):89–97.
  • Liu T, Yao M, Liu S, et al. Serum Golgi protein 73 is not a suitable diagnostic marker for hepatocellular carcinoma. Oncotarget 2017;8(10):16498–16506. doi:10.18632/oncotarget.14954.
  • Marrero JA, Feng Z, Wang Y, et al. Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology. 2009;137(1):110–118. doi:10.1053/j.gastro.2009.04.005.
  • Dahmen U, Qian S, Rao AS, et al. Split tolerance induced by orthotopic liver transplantation in mice. Transplantation. 1994;58(1):1–8.
  • Crispe IN, Dao T, Klugewitz K, et al. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev. 2000;174:47–62.
  • Crispe IN, Giannandrea M, Klein I, et al. Cellular and molecular mechanisms of liver tolerance. Immunol Rev. 2006;213(1):101–118. doi:10.1111/j.1600-065X.2006.00435.x.
  • Moris D, Lu L, Qian S. Mechanisms of liver-induced tolerance. Curr Opin Organ Transplant. 2016;22(1):1– 78. doi:10.1097/MOT.0000000000000380.
  • Moris D, Rahnemai-Azar AA, Zhang X, et al. Program death-1 immune checkpoint and tumor microenvironment in malignant liver tumors. Surg Oncol. 2017;26(4):423–430. doi:10.1016/j.suronc.2017.08.005.
  • Fang X, Zheng P, Tang J, et al. CD24: from A to Z. Cell Mol Immunol. 2010;7(2):100–103. doi:10.1038/cmi.2009.119.
  • Castelli G, Pelosi E, Testa U. Liver cancer: molecular characterization, clonal evolution and cancer stem Cells. Cancers. 2017;9(9):127. doi:10.3390/cancers9090127.
  • Wan X, Cheng C, Shao Q, et al. CD24 promotes HCC progression via triggering Notch-related EMT and modulation of tumor microenvironment. Tumor Biol. 2016;37(5):6073–6084. doi:10.1007/s13277-015-4442-7.
  • Liu AY, Cai Y, Mao Y, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis. 2014;35(3):537–545. doi:10.1093/carcin/bgt364.
  • Zhang P, Maimaitiming A, Zhou X, et al. Clinicopathological and prognostic value of plasma CD24 level in hepatocellular carcinoma. J Invest Surg. 2018;33(6):536–541.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.